In the context that infectious diseases continue to pose many challenges to the preventive health system, Naviva Group has organized a series of scientific seminars/activities to update in-depth knowledge about chickenpox prevention and share improvements in the application of the MAV/06 vaccine in preventive health practice.
Focus on proactive disease prevention
Chickenpox is an infectious disease that tends to increase during the transitional season and breaks out strongly in the first months of the year, especially when children live and study in crowded environments.
According to data from the Pasteur Institute of Ho Chi Minh City, 90% of cases are concentrated in children aged 2–7 years old [1]. The disease has a potential for rapid spread and potential risk of dangerous complications if not prevented and monitored properly.
In recent years, preventive medicine has increasingly been considered an important pillar in the strategy of protecting public health.
Faced with the complicated developments of infectious diseases, timely updating scientific evidence, professional guidance and new vaccination protocols are considered key factors, helping the medical team improve disease prevention efficiency and adapt to the increasing requirements of community health care.
Update on scientific advances in the MAV/06 strain
At the workshop, Dr. Le Thi Hai Yen - Head of Training and Quality Management Department of Naviva Group shared a topic on "Improving the quality of chickenpox vaccine using MAV/06 strain".
The report focuses on analyzing the development history and practical application process of this virus strain, which has been deployed in South Korea since 1993 and included in the National Expanded Program on Immunization.
According to Dr. Yen, the first generation chickenpox vaccine from the MAV/06 strain has been licensed for circulation in more than 30 countries, with over 30 million doses used, of which Vietnam started implementation in 2008.
Post-circulation monitoring data shows stable protection effectiveness and high safety, creating a scientific premise for research and development of improved vaccine generations.
From that foundation, the 2nd generation MAV/06 chickenpox vaccine has been upgraded in production technology, applying the MRC-5 cell line as recommended by WHO, along with an automated, closed production process and no antibiotics in the composition, bringing a generation of vaccines with high stability, meeting the requirements for quality and safety in current vaccination.
Chickenpox vaccination according to the latest recommendations of the World Health Organization (WHO) on chickenpox vaccine
Inheriting the foundation from MAV/06 generation 1, with important improvements, the MAV/06 chickenpox vaccine generation 2 has met the quality and safety standards of the WHO and has been pre-assessed by the WHO (WHO PQ). The product is confirmed to have safety and immunogenicity equivalent to vaccines using the Oka strain currently in circulation and currently MAV/06 generation 2 is exclusively distributed in Vietnam.
In the latest recommendation, WHO proposed a two-dose injection regimen to achieve optimal protection against chickenpox, with a significantly higher level of protection than the one-dose injection schedule.
At the same time, WHO also noted that the switch between reducing virulence live chickenpox vaccines using Oka strains and MAV/06 strains is safe, and no adverse reactions were recorded in healthy children vaccinated.
Accompanying a healthy community
In Vietnam, Naviva Group is the unit authorized to distribute the MAV/06 generation chickenpox vaccine – BARYCELA inj. in Vietnam, accompanying medical facilities in improving the quality and effectiveness of vaccination.
The supply of international standard vaccines helps strengthen resources for the immunization system, especially in chickenpox prevention, thereby contributing to improving the effectiveness of preventive medicine and protecting public health.
Through seminars/scientific activities, Naviva Group affirms its role in connecting international vaccine manufacturers and the domestic health system, contributing to supporting medical staff to update knowledge, improve the quality of vaccination practice and enhance chickenpox prevention effectiveness.
BARYCELA Inj., a new generation chickenpox vaccine developed by GC Biopharma from MAV/06, achieves immune efficacy and safety equivalent to Oka vaccine, and can be used in the current two-dose injection schedule [10].
Recommended 2-dose vaccination schedule to create optimal immunity
12 months – 12 years old:
- Nose 1: from 12 months old
- Dose 2: at least 3 months after dose 1 or booster shot when children are 4–6 years old.
In Vietnam, NAVIVA GROUP is the unit authorized to distribute the MAV/6 generation 2 chickenpox vaccine called BARYCELA inj. (GC Biopharma – Korea) in Vietnam. With more than 21 years of experience in the field of vaccines and medical biologicals, NAVIVA GROUP cooperates with medical facilities to enhance access to safe – effective – quality vaccines for the community.
The unit commits to ensuring stable supply, strictly complying with the preservation - transportation process according to GSP/GDP standards; and accompanying activities to raise awareness about proactive and safe vaccination.
💭Hotline for consultation: 0905 584 666
Facebook Website: www. naviva. com. vn
Facebook Email: info@naviva. com. vn
